Literature DB >> 29473625

Enhancing the quality of care for patients with multiple sclerosis through performance improvement CME.

Bruce A Cohen1, Ben W Thrower1, Carolyn A Berry1, Stephanie A Stowell1, William A Mencia1, Rachel B Karcher1.   

Abstract

Multiple sclerosis (MS) is an inflammatory neurodegenerative disease marked by a heterogeneous clinical presentation and disease course. Although improvements in the recognition and management of MS have been made in recent years, challenges remain due to the complex nature of the disease. Clinicians must remain current with their skills as knowledge surrounding MS care continues to advance. Here we report results of a performance improvement (PI) continuing medical education (CME) activity that was designed to promote evidence-based care of patients with MS. Participants demonstrated significant improvements in assessing disease-related complications, treating cognitive dysfunction, assessing adherence, and providing disease-related educational materials. These data support the role of PI CME in improving clinician practices that align with quality MS patient care.

Entities:  

Year:  2013        PMID: 29473625      PMCID: PMC5798514          DOI: 10.1212/CPJ.0b013e318296f2bc

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  11 in total

1.  Capacity to make medical treatment decisions in multiple sclerosis: a potentially remediable deficit.

Authors:  Michael R Basso; Philip J Candilis; Jay Johnson; Courtney Ghormley; Dennis R Combs; Taeh Ward
Journal:  J Clin Exp Neuropsychol       Date:  2010-12       Impact factor: 2.475

2.  Identification, causation, alleviation, and prevention of complications (ICAP): an approach to symptom and disability management in multiple sclerosis.

Authors:  Bruce A Cohen
Journal:  Neurology       Date:  2008-12-09       Impact factor: 9.910

3.  A report of quality improvement in the care of patients with acute coronary syndromes.

Authors:  Christopher P Cannon; James W Hoekstra; David M Larson; Rachel Bongiorno Karcher; William A Mencia; Carolyn A Berry; Stephanie A Stowell
Journal:  Crit Pathw Cardiol       Date:  2011-03

4.  Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial.

Authors:  J F Lovera; E Frohman; T R Brown; D Bandari; L Nguyen; V Yadav; O Stuve; J Karman; K Bogardus; G Heimburger; L Cua; G Remingon; J Fowler; T Monahan; S Kilcup; Y Courtney; J McAleenan; K Butler; K Wild; R Whitham; D Bourdette
Journal:  Mult Scler       Date:  2010-05-18       Impact factor: 6.312

Review 5.  Improving quality of life in multiple sclerosis: an unmet need.

Authors:  Howard L Zwibel; Jennifer Smrtka
Journal:  Am J Manag Care       Date:  2011-05       Impact factor: 2.229

6.  Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns.

Authors:  K E T O'Rourke; M Hutchinson
Journal:  Mult Scler       Date:  2005-02       Impact factor: 6.312

7.  Quality indicators for multiple sclerosis.

Authors:  Eric M Cheng; Carolyn J Crandall; Christopher T Bever; Barbara Giesser; Jodie K Haselkorn; Ron D Hays; Paul Shekelle; Barbara G Vickrey
Journal:  Mult Scler       Date:  2010-06-18       Impact factor: 6.312

Review 8.  Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command.

Authors:  Mark S Freedman; Bruce Cohen; Suhayl Dhib-Jalbut; Douglas Jeffery; Anthony T Reder; Magnhild Sandberg-Wollheim; Bianca Weinstock-Guttman
Journal:  Curr Med Res Opin       Date:  2009-10       Impact factor: 2.580

9.  Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis.

Authors:  Jennifer Elston Lafata; Mirela Cerghet; Elizabeth Dobie; Lonni Schultz; Kaan Tunceli; Jacqueline Reuther; Stanton Elias
Journal:  J Am Pharm Assoc (2003)       Date:  2008 Nov-Dec

Review 10.  Cognitive impairment in multiple sclerosis.

Authors:  Jesus Lovera; Blake Kovner
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.